Cargando…
Pregnanetriol in the Range of 1.2–2.1 mg/m(2)/day as an Index of Optimal Control in CYP21A2 Deficiency
Auxological data is the gold standard index of the therapeutic condition in CYP21A2 deficiency over a long-range period, whereas urinary pregnanetriol for 24 h (PT) is variable for a shorter-range period. Ideal PT levels in comparison with auxological data have not been reported. The main purpose of...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society for Pediatric Endocrinology
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004871/ https://www.ncbi.nlm.nih.gov/pubmed/24790344 http://dx.doi.org/10.1297/cpe.16.45 |
_version_ | 1782314024869822464 |
---|---|
author | Izawa, Masako Aso, Keiko Higuchi, Asako Ariyasu, Daisuke Hasegawa, Yukihiro |
author_facet | Izawa, Masako Aso, Keiko Higuchi, Asako Ariyasu, Daisuke Hasegawa, Yukihiro |
author_sort | Izawa, Masako |
collection | PubMed |
description | Auxological data is the gold standard index of the therapeutic condition in CYP21A2 deficiency over a long-range period, whereas urinary pregnanetriol for 24 h (PT) is variable for a shorter-range period. Ideal PT levels in comparison with auxological data have not been reported. The main purpose of this study was to analyze ideal PT values as an index of optimal control for CYP21A2 deficiency. First, inter-daily fluctuation of PT was analyzed in one participant. PT levels were distributed over a wide range of 0.44–14.7 mg/day (n=42) in this participant, suggesting that the therapeutic condition should be judged by multiple PT samples. Second, the therapeutic periods of 15 participants with CYP21A2 deficiency were classified using auxological data and Cushing-like symptoms, and the PT levels were analyzed in each period retrospectively. The 95% confidence intervals for the means of the PT levels in the excessive, good and poor control periods were 0.03–1.25 (n=26), 1.23–2.09 (n=116), and 5.35–8.37 (n=72) mg/m(2)/day, respectively. In conclusion, 1.2–2.1 mg/m(2)/day of PT values can be used as an index of optimal control in CYP21A2 deficiency. |
format | Online Article Text |
id | pubmed-4004871 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | The Japanese Society for Pediatric Endocrinology |
record_format | MEDLINE/PubMed |
spelling | pubmed-40048712014-04-30 Pregnanetriol in the Range of 1.2–2.1 mg/m(2)/day as an Index of Optimal Control in CYP21A2 Deficiency Izawa, Masako Aso, Keiko Higuchi, Asako Ariyasu, Daisuke Hasegawa, Yukihiro Clin Pediatr Endocrinol Original Article Auxological data is the gold standard index of the therapeutic condition in CYP21A2 deficiency over a long-range period, whereas urinary pregnanetriol for 24 h (PT) is variable for a shorter-range period. Ideal PT levels in comparison with auxological data have not been reported. The main purpose of this study was to analyze ideal PT values as an index of optimal control for CYP21A2 deficiency. First, inter-daily fluctuation of PT was analyzed in one participant. PT levels were distributed over a wide range of 0.44–14.7 mg/day (n=42) in this participant, suggesting that the therapeutic condition should be judged by multiple PT samples. Second, the therapeutic periods of 15 participants with CYP21A2 deficiency were classified using auxological data and Cushing-like symptoms, and the PT levels were analyzed in each period retrospectively. The 95% confidence intervals for the means of the PT levels in the excessive, good and poor control periods were 0.03–1.25 (n=26), 1.23–2.09 (n=116), and 5.35–8.37 (n=72) mg/m(2)/day, respectively. In conclusion, 1.2–2.1 mg/m(2)/day of PT values can be used as an index of optimal control in CYP21A2 deficiency. The Japanese Society for Pediatric Endocrinology 2007-05-17 2007 /pmc/articles/PMC4004871/ /pubmed/24790344 http://dx.doi.org/10.1297/cpe.16.45 Text en 2007©The Japanese Society for Pediatric Endocrinology http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. |
spellingShingle | Original Article Izawa, Masako Aso, Keiko Higuchi, Asako Ariyasu, Daisuke Hasegawa, Yukihiro Pregnanetriol in the Range of 1.2–2.1 mg/m(2)/day as an Index of Optimal Control in CYP21A2 Deficiency |
title | Pregnanetriol in the Range of 1.2–2.1 mg/m(2)/day as an Index of
Optimal Control in CYP21A2 Deficiency |
title_full | Pregnanetriol in the Range of 1.2–2.1 mg/m(2)/day as an Index of
Optimal Control in CYP21A2 Deficiency |
title_fullStr | Pregnanetriol in the Range of 1.2–2.1 mg/m(2)/day as an Index of
Optimal Control in CYP21A2 Deficiency |
title_full_unstemmed | Pregnanetriol in the Range of 1.2–2.1 mg/m(2)/day as an Index of
Optimal Control in CYP21A2 Deficiency |
title_short | Pregnanetriol in the Range of 1.2–2.1 mg/m(2)/day as an Index of
Optimal Control in CYP21A2 Deficiency |
title_sort | pregnanetriol in the range of 1.2–2.1 mg/m(2)/day as an index of
optimal control in cyp21a2 deficiency |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004871/ https://www.ncbi.nlm.nih.gov/pubmed/24790344 http://dx.doi.org/10.1297/cpe.16.45 |
work_keys_str_mv | AT izawamasako pregnanetriolintherangeof1221mgm2dayasanindexofoptimalcontrolincyp21a2deficiency AT asokeiko pregnanetriolintherangeof1221mgm2dayasanindexofoptimalcontrolincyp21a2deficiency AT higuchiasako pregnanetriolintherangeof1221mgm2dayasanindexofoptimalcontrolincyp21a2deficiency AT ariyasudaisuke pregnanetriolintherangeof1221mgm2dayasanindexofoptimalcontrolincyp21a2deficiency AT hasegawayukihiro pregnanetriolintherangeof1221mgm2dayasanindexofoptimalcontrolincyp21a2deficiency |